hepatocellular carcinoma, HCC
Conditions
Interventions
Group 1 :TACE+HAIC+Targeted Therapy + Immunotherapy
Group 2 :TACE+Targeted Therapy + Immunotherapy
Sponsors
The First Affiliated Hospital of Bengbu Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Willingness to participate in the study and sign the informed consent form; 2. Aged 18 or above, regardless of gender; 3. Hepatocellular carcinoma confirmed by pathological histology, cytology, or imaging; 4. Subjects with hepatocellular carcinoma at CNLC IIb/IIIa/IIIb stage or BCLC B/C stage; 5. Determined by the attending physician to be suitable for first-line transarterial chemoembolization (TACE) and/or hepatic arterial infusion chemotherapy (HAIC) combined with systemic drug therapy.
Exclusion criteria
Exclusion criteria: 1. Contraindications to TACE, HAIC, or systemic therapy (e.g., severe liver cirrhosis, ascites =moderate, Child - Pugh class C liver function unresponsive to hepatoprotective therapy). 2. Inability to adequately participate in the study. 3. Pregnant or breastfeeding women. 4. Participation in another clinical trial within the past three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Progression free survival;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactYan Yang
The First Affiliated Hospital of Bengbu Medical University
Outcome results
None listed